

# THE ROLE OF I-J AND Igh DETERMINANTS ON F<sub>1</sub>- DERIVED SUPPRESSOR FACTOR IN CONTROLLING RESTRICTION SPECIFICITY\*

BY MUTSUHIKO MINAMI, ICHIRO AOKI, NAOKI HONJI, CARL R.  
WALTENBAUGH, AND MARTIN E. DORF

*From the Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115;  
and Department of Microbiology, Northwestern Medical School, Chicago, Illinois 60611*

Over the past decade there have been numerous descriptions of suppressor T cells (Ts) and of factors derived from such cells. Several apparently related, but nonidentical, suppressor regulatory pathways consisting of a variety of T-T interactions have been described (1-4). Our laboratory has concentrated on one of these models of antigen-specific suppression involving the hapten 4-hydroxy-3-nitrophenyl acetyl (NP). In the NP model system, we have identified at least three distinct suppressor T cell subsets (Ts<sub>1</sub>, Ts<sub>2</sub>, Ts<sub>3</sub>) (5-7). Furthermore, we have demonstrated a requirement for accessory cells at various points in the suppressor pathway (8, 9). All of these cellular elements are needed to modulate the contact sensitivity (CS) response to NP. Furthermore, the same T cell populations are required for suppression of NP-specific plaque-forming cell (PFC) responses (10, 11).

The final effector T cell population in the suppressor cell cascade appears to be an Lyt-2<sup>+</sup> subset that we have termed Ts<sub>3</sub> (6). Ts<sub>3</sub> cells are induced as a consequence of conventional immunization concomitant with the induction of T cells mediating helper or CS activity (8, 12). However, these primed Ts<sub>3</sub> cells appear to remain inactive until appropriately triggered by Ts<sub>2</sub> cells or a factor derived from Ts<sub>2</sub> cells (12, 13). The Ts<sub>3</sub> cells are antigen-specific and bind to NP-coated petri dishes (6, 7, 14). They react with anti-Thy-1, anti-Lyt-2, anti-I-J, and anti-NP<sup>b</sup> (antiidiotypic) antisera (6, 7, 14). The activity of Ts<sub>3</sub> cells can be demonstrated in cyclophosphamide-treated recipients and is restricted by I-J and Igh genes (6, 12).

Ts<sub>3</sub> hybridomas that constitutively secrete a suppressor factor, TsF<sub>3</sub>, have been obtained in the NP system. Five hybridoma T cell lines were prepared by fusion of C57BL/6 (B6) or CKB derived Ts<sub>3</sub> cells with the BW5147 thymoma (7). The supernatants from these Ts<sub>3</sub> cell hybridomas contain factors (TsF<sub>3</sub>) which, like Ts<sub>3</sub> cells have the capacity to specifically suppress NP-induced CS responses (7).

\* *Abbreviations used in this paper:* B6, C57BL/6 mice; CS, contact sensitivity; CY, cyclophosphamide; DMSO, dimethylsulfoxide; DNFB, 2,4-dinitrofluorobenzene; GAT, poly-(L-glu<sup>60</sup>, L-ala<sup>50</sup>, L-tyr<sup>10</sup>); KLH, keyhole limpet hemocyanin; NP, 4-hydroxy-3-nitrophenyl acetyl hapten; NP-O-Su, NP-succinimide ester; PBS, phosphate-buffered saline; PFC, plaque-forming cell; RAMG, rabbit anti-mouse immunoglobulin; Ts<sub>1</sub>, Ts<sub>2</sub>, Ts<sub>3</sub> first-, second, and third-order suppressor T cells; TsF<sub>1</sub>, TsF<sub>2</sub>, TsF<sub>3</sub>, suppressor factors derived from Ts<sub>1</sub>, Ts<sub>2</sub>, and Ts<sub>3</sub> cells.

<sup>1</sup> Supported by grants AI-16677 and AI-18072 from the NIH.

Suppression of CS responses is only observed if TsF<sub>3</sub> is administered during the effector phase of the immune response. TsF<sub>3</sub> reacts with allele-specific anti-I-J and anti-NP<sup>b</sup> antisera and has binding specificity for the NP hapten (7). Furthermore, TsF<sub>3</sub> does not suppress I-J incompatible mice. In addition to this H-2 restriction, the monoclonal TsF<sub>3</sub> factors also demonstrate Igh genetic restrictions. Thus, TsF<sub>3</sub> displays dual genetic restrictions for both I-J and Igh linked genes (7).

Taniguchi et al. (15, 16) have shown that a KLH-specific TsF<sub>3</sub>-like factor consists of a molecular dimer composed of a I-J-related piece (28,000 daltons) and an antigen-binding piece that bears determinants encoded by Igh-linked genes. The latter piece may have a membrane (45,000 daltons) and secretory (35,000 daltons) form (15). We have performed similar studies to analyze the molecular organization of the NP-specific TsF<sub>3</sub> (17). Thus, NP-specific TsF<sub>3</sub> was reduced and passed over antigen or anti-I-J immunoadsorbent columns. The activity of the reduced TsF<sub>3</sub> could not be recovered in the eluate or filtrate fractions from either column. However, suppressor activity was reconstituted by combining the appropriate filtrate and eluate fractions (17). These results are similar to those described by Taniguchi et al. for KLH-specific TsF (15, 16). The data imply a two-chain disulfide-linked structure for TsF<sub>3</sub>, one chain binds antigen and the other bears I-J-related determinants. To determine if the same class of TsF<sub>3</sub> molecules were responsible for suppression of PFC responses, some of these fractions were also tested for suppressive activity in vitro, using NP-ficoll cultures (11). The data demonstrated that hybridoma-derived TsF<sub>3</sub> molecules with similar biophysical characteristics were responsible for suppression of both CS and PFC responses (11, 17).

Since TsF<sub>3</sub> is dual restricted and consists of a two-chain structure, we considered the possibility that each chain controlled one of the genetic restrictions. Efforts to physically separate and reassociate the chains from different TsF sources have failed in another system (18). Therefore, we used another approach to analyze this issue. The genetic restrictions of Ts<sub>3</sub> cells from NP-primed H-2 and Igh heterozygous (B6 × C3H)F<sub>1</sub> mice were analyzed. Four cloned F<sub>1</sub>-derived Ts<sub>3</sub> hybridoma lines were established. The properties of these clones are the subject of the present report.

### Materials and Methods

*Mice.* All mice were either purchased from The Jackson Laboratory, Bar Harbor, ME or bred in the animal facilities at Harvard Medical School, Boston, MA. Mice were used at 2–5 mo of age and were maintained on laboratory chow and acidified, chlorinated water ad lib.

Animals used in the study were maintained in accordance with the guidelines of the Committee on Animals of the Harvard Medical School and those prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council (DHEW publication No. (NIH) 78-23).

*Antigen.* NP-O-Succinimide (NP-O-Su) was purchased from the Biosearch Co., San Rafael, CA, Dimethylsulfoxide (DMSO) was purchased from Fisher Scientific Co., Pittsburgh, PA. 2,4-dinitro-1-fluorobenzene (DNFB) was obtained from Eastman Kodak Co., Rochester, NY.

*Antisera.* Both B10.A(3R) anti-B10.A(5R) (anti-I-J<sup>b</sup>) and B10.A(5R) anti-B10.(3R) (anti-I-J<sup>b</sup>) were produced by immunization with spleen and lymph node cells, as described

elsewhere (19). Monoclonal anti-I-J antibodies, WF8.C2.4 (anti-I-J<sup>k</sup>), WF8.D2.3 (anti-I-J<sup>k</sup>), and WF9.40.5 (anti-I-J<sup>b</sup>) were characterized previously (20, 21). Both monoclonal anti-Thy-1.1 and Thy-1.2 antibodies were purchased from New England Nuclear, Boston, MA. Guinea pig anti-CGAT, anti-NP<sup>b</sup> and anti-NP<sup>j</sup> antiidiotypic antisera were prepared as detailed elsewhere (19). These reagents detect a common idiotype on anti-GAT, C57BL/6 anti-NP, and C3H anti-NP antibodies, respectively, and have been described previously (22, 23).

*In Vitro Activation of NP-primed Lymph Node Ts<sub>3</sub> Cells with TsF<sub>2</sub>.* Regional lymph node cells from mice that had been immunized subcutaneously with 2 mg NP-O-Su were used as the source of Ts<sub>3</sub> cells (12). B6-Ts<sub>2</sub>-28, C3H.SW-Ts<sub>2</sub>-7, and CKB-Ts<sub>2</sub>-59-derived TsF<sub>2</sub>, which have been previously characterized and described (12, 24), were used for activation of lymph node Ts<sub>3</sub> cells in vitro.  $5 \times 10^7$  NP-primed lymph node cells were cultured for 2 h in 10 ml RMPI 1640 with 10% fetal calf serum and 0.1 mM Hepes plus 50  $\mu$ l TsF<sub>2</sub> ascites fluid derived from B6-Ts<sub>2</sub>-28, CKB-Ts<sub>2</sub>-59 C3H.SW-Ts<sub>2</sub>-7, or BW5147 cells that were grown in (AKR  $\times$  B6)F<sub>1</sub>, (AKR  $\times$  CKB)F<sub>1</sub>, (AKR  $\times$  C3H.SW)F<sub>1</sub>, or AKR mice, respectively. After culture, these activated lymph node cells were washed three times with Hanks' balanced salt solution and resuspended.

*Functional Analysis of the Activated NP-primed Lymph Node Ts<sub>3</sub> Cells in Cyclophosphamide-treated Antigen-primed Mice.* Mice were primed subcutaneously with 2 mg of NP-O-Su in DMSO on day 0, as described elsewhere (12). 24 h later, they were treated with an intraperitoneal injection of 20 mg/kg cyclophosphamide (CY) in saline. On day 6, each mouse received intravenously  $1 \times 10^7$  NP-primed lymph node cells activated with TsF<sub>2</sub> or control BW5147 factors, as described above, or received 0.5 ml of TsF<sub>2</sub> or control BW5147 factors. Immediately after transfer, mice were challenged for CS responses. It should be noted that  $1 \times 10^7$  immune lymph node cells are not sufficient to transfer immunity under these experimental conditions.

*Preparation of Ts<sub>3</sub> Cells from Antigen Plates.* The methods for the preparation and enrichment of NP-binding T cells were described in detail elsewhere (7, 14). In brief,  $5 \times 10^7$  regional lymph node cells from (C57BL/6  $\times$  C3H)F<sub>1</sub> mice that were immunized subcutaneously with 2 mg NP-O-Su were added to purified anti-mouse immunoglobulin (RAMG)-coated petri dishes to remove B cells. The nonadherent T cells were incubated on NP-bovine serum albumin-coated petri dishes for 45 min at room temperature. Nonadherent cells were removed by gentle swirling, and the plates were placed on ice for 20 min. The antigen-binding cells were collected from the plate by gentle pipetting and used as the source of Ts<sub>3</sub> cells.

*Hybridization and Screening of Ts<sub>3</sub> Hybridoma Lines.* Ts<sub>3</sub>-enriched (C57BL/6  $\times$  C3H)F<sub>1</sub> lymphocytes were hybridized with BW5147 T lymphoma cells. The polyethylene glycol-mediated hybridizing method was exactly the same as previously reported (7, 19). The hybridized Ts<sub>3</sub> candidates were screened using a cytotoxicity test (19) with allele-specific anti-I-J reagents. Two fusions were performed and  $\sim 500$  colonies were screened.

All of the hybridomas were cultured in RMPI 1640 containing 8% fetal calf serum and 0.01 M Hepes buffer. The suppressor factors used in the present experiment were collected from the cultured supernatants of cells at an approximate density of  $7 \times 10^5$  cells/ml in the above medium.

*Adsorption and Elution of TsF.* The method of adsorption and elution of TsF using protein-conjugated Sepharose-4B columns were described in detail previously (25).

*Assay for Suppressive Activity of TsF on NP-mediated Cutaneous or Contact Sensitivity (CS) Responses.* The assay for NP-specific CS responses was described elsewhere (26). Briefly, each animal was primed subcutaneously with 1 or 2 mg of NP-O-Su in DMSO. Unless indicated otherwise, the hybridoma factors were tested in the effector phase, 5 and/or 6 d after priming. 0.4 ml of each hybridoma supernatant or BW5147 control supernatant was injected i.v. on the day before and the day of antigen challenge (6 d after immunization). Mice were challenged in the left footpad with 0.025 ml phosphate-buffered saline (PBS) solution containing 30  $\mu$ g of NP-O-Su (prepared by mixing 25  $\mu$ l of a 2% NP-O-Su/DMSO solution in 0.4 ml PBS). Footpad swelling was measured 24 h after challenge. Swelling was determined as the difference in units of  $10^{-3}$  cm between the left and right

footpad thickness.

*DNFB Contact Sensitivity Responses.* Contact sensitivity was induced by two daily paintings on the shaved abdomen with 25  $\mu$ l of 0.5% DNFB solution in acetone olive oil (4:1) (25). 6 d after the last painting 20  $\mu$ l of 0.2% DNFB in the same vehicle was applied to the left ear and the ear swelling was measured as the difference between the left and right ear thickness.

*Percent Suppression.* The percent suppression in the present study was calculated by the following formula: percent suppression =  $100 \times [(\text{swelling of BW5147 tumor supernatant injected group} - \text{swelling of TsF injected group}) / (\text{swelling of BW5147 tumor supernatant injected group} - \text{swelling of unprimed group})]$ .

*Data Analysis.* Statistical analysis of experimental data with respect to controls was calculated using two-tailed Student's *t* test.

## Results

Our initial experiments were designed to analyze the specificity of Ts<sub>3</sub> populations derived from H-2 and Igh heterozygous (B6  $\times$  C3H)F<sub>1</sub> mice. One purpose of these studies was to determine whether we could identify Ts<sub>3</sub> populations in which the H-2 restriction specificity was derived from one parent and the Igh restriction specificity was derived from the other parent. Ts<sub>3</sub> cells were generated in (B6  $\times$  C3H)F<sub>1</sub> donors (H-2<sup>b</sup>; Igh<sup>b</sup>/H-2<sup>k</sup>; Igh<sup>b</sup>) by s.c. priming with 2 mg NP-O-Su. After 6 d,  $1 \times 10^7$  draining lymph node cells that had been activated in vitro with monoclonal TsF<sub>2</sub> from a variety of sources were adoptively transferred to NP-primed cyclophosphamide (CY)-treated C57BL/6 (H-2<sup>b</sup>; Igh<sup>b</sup>), C3H.SW (H-2<sup>b</sup>; Igh<sup>b</sup>), C3H (H-2<sup>k</sup>; Igh<sup>b</sup>), CKB (H-2<sup>k</sup>; Igh<sup>b</sup>), or (B6  $\times$  C3H)F<sub>1</sub> recipients. The CY treatment functionally eliminates Ts<sub>3</sub> generation in the recipients, as evidenced by the inability of TsF<sub>2</sub> to suppress CS responses in CY-treated animals (Table I). This reconstitution protocol allows direct analysis of Ts<sub>3</sub> activity by the adoptively transferred cell population. The recipients were challenged immediately after cell transfer. Footpad swelling was measured 24 h after challenge. The data in Table I summarize the results of seven experiments using this in vivo system. (B6  $\times$  C3H)F<sub>1</sub> Ts<sub>3</sub> cells that were transferred to CY-treated B6 recipients, were only activated following coculture with B6-derived TsF<sub>2</sub>, suppression was not observed following activation with CKB, or C3H.SW-derived TsF<sub>2</sub> in these recipients. When the same Ts<sub>3</sub> cell population was adoptively transferred to C3H.SW recipients, only the C3H.SW-derived TsF<sub>2</sub> activated these cells to mediate their suppressive activity. The TsF<sub>2</sub> derived from H-2-compatible Igh-incompatible B6 donors, was functionally unable to activate (B6  $\times$  C3H)F<sub>1</sub> Ts<sub>3</sub> cells when assayed in C3H.SW recipients, although as shown above the same F1-derived Ts<sub>3</sub> population was functional when assayed in B6 recipients. Similarly, only CKB-derived TsF<sub>2</sub> was capable of activating the (B6  $\times$  C3H)F<sub>1</sub>-derived Ts<sub>3</sub> population to express functional suppressive activity in CKB or B10.BR recipients. TsF<sub>2</sub> derived from H-2-incompatible B6 donors was unable to activate the (B6  $\times$  C3H)F<sub>1</sub> Ts<sub>3</sub> subpopulation to mediate suppression in CKB or B10.BR recipients. Furthermore, neither B6, C3H.SW, or CKB-derived TsF<sub>2</sub> could activate (B6  $\times$  C3H)F<sub>1</sub> Ts<sub>3</sub> cells that were adoptively transferred to C3H recipients. Unfortunately, we have not prepared a monoclonal C3H-derived TsF<sub>2</sub> to serve as positive control for the latter groups. Nonetheless, it appears that the (B6  $\times$  C3H)F<sub>1</sub> Ts<sub>3</sub> population, consists of at least three and probably four functionally distinct subsets; each Ts<sub>3</sub> subset was restricted to one

TABLE I  
*Activation of H-2 and Igh Heterozygous Ts<sub>3</sub> Cells with Monoclonal Suppressor Factors<sup>‡</sup>*

CY-treated recipient	Ts <sub>3</sub> donor	TsF <sub>2</sub> source for Ts <sub>3</sub> activation	Footpad swelling ± SE <sup>§</sup>
C57BL/6	(B6 × C3H)F <sub>1</sub>	BW5147	35.5 ± 2.2 (17)
	(B6 × C3H)F <sub>1</sub>	B6-Ts <sub>2</sub> -28	19.1 ± 2.0 (17)*
	(B6 × C3H)F <sub>1</sub>	C3H.SW-Ts <sub>2</sub> -7	33.7 ± 1.3 (16)
	(B6 × C3H)F <sub>1</sub>	CKB-Ts <sub>2</sub> -59	34.5 ± 2.4 (4)
	None	BW5147	33.8 ± 1.9 (9)
C3H.SW	None	B6-Ts <sub>2</sub> -28	32.9 ± 2.8 (7)
	(B6 × C3H)F <sub>1</sub>	BW5147	32.8 ± 1.4 (23)
	(B6 × C3H)F <sub>1</sub>	B6-Ts <sub>2</sub> -28	33.8 ± 2.3 (20)
	(B6 × C3H)F <sub>1</sub>	C3H.SW-Ts <sub>2</sub> -7	19.9 ± 1.5 (20)*
	(B6 × C3H)F <sub>1</sub>	CKB-Ts <sub>2</sub> -59	33.8 ± 2.1 (4)
C3H	None	BW5147	34.9 ± 2.9 (9)
	None	C3W.SW-Ts <sub>2</sub> -7	30.9 ± 2.5 (8)
	(B6 × C3H)F <sub>1</sub>	BW5147	36.2 ± 2.8 (12)
	(B6 × C3H)F <sub>1</sub>	B6-Ts <sub>2</sub> -28	35.4 ± 2.7 (11)
	(B6 × C3H)F <sub>1</sub>	C3H.SW-Ts <sub>2</sub> -7	34.2 ± 2.2 (13)
CKB or B10.BR	(B6 × C3H)F <sub>1</sub>	CKB-Ts <sub>2</sub> -59	33.9 ± 3.6 (8)
	(B6 × C3H)F <sub>1</sub>	BW5147	37.4 ± 2.2 (8)
	(B6 × C3H)F <sub>1</sub>	B6-Ts <sub>2</sub> -28	37.8 ± 1.9 (9)
	(B6 × C3H)F <sub>1</sub>	C3H.SW-Ts <sub>2</sub> -7	38.1 ± 2.1 (8)
	(B6 × C3H)F <sub>1</sub>	CKB-Ts <sub>2</sub> -59	24.2 ± 1.8 (9)*
(B6 × C3H)F <sub>1</sub>	None	BW5147	39.5 ± 4.2 (4)
	None	CKB-Ts <sub>2</sub> -59	36.0 ± 2.3 (4)
	(B6 × C3H)F <sub>1</sub>	BW5147	32.0 ± 1.8 (4)
	(B6 × C3H)F <sub>1</sub>	B6-Ts <sub>2</sub> -28	18.5 ± 1.3 (4)*
	(B6 × C3H)F <sub>1</sub>	C3H.SW-Ts <sub>2</sub> -7	22.7 ± 2.3 (3)*
(B6 × C3H)F <sub>1</sub>	(B6 × C3H)F <sub>1</sub>	CKB-Ts <sub>2</sub> -59	18.3 ± 1.7 (4)*
	None	BW5147	30.0 ± 1.6 (5)
	None	B6-Ts <sub>2</sub> -28	32.3 ± 2.6 (4)

<sup>‡</sup> In vitro activation of regional lymph node Ts<sub>3</sub> cells from NP-O-Su-primed mice with TsF<sub>2</sub> was done as described in Materials and Methods. Activation was continued for 2 h. Recipient mice were primed with NP-O-Su; 24 h later all mice were given 20 mg/kg cyclophosphamide, and 6 d later received 1 × 10<sup>7</sup> activated Ts<sub>3</sub> before antigen challenge. The data represent the pooled results from seven separate experiments (not all groups were included in each experiment).

<sup>§</sup> The data from seven experiments were pooled and expressed as the increment of footpad swelling ± SE in units of 10<sup>-5</sup> cm. The background responses of nonimmunized mice ranged from 4.5 to 13.7. The number of mice tested is indicated in parentheses. An asterisk indicates significant suppression, P < 0.01.

parental H-2 and Igh specificity. Furthermore, the data suggest that each Ts<sub>3</sub> subpopulation must be activated by a TsF<sub>2</sub>, which must share the same H-2 and Igh restriction as the Ts<sub>3</sub> population. Finally, we noted that when (B6 × C3H)F<sub>1</sub> recipients were used, either TsF<sub>2</sub> could activate the Ts<sub>3</sub> subsets to express suppressive activity (Table I).

The present data extend previous results in this system by demonstrating that Ts<sub>3</sub> cells derived from H-2 and Igh heterozygous F<sub>1</sub> mice can contain four distinct populations of Ts<sub>3</sub> cells, each restricted to a particular combination of H-2 and Igh controlled specificities. However, to formally confirm these conclusions, which are based on analysis of heterogeneous cell populations, we undertook to demonstrate the same phenomenon at the clonal level. Therefore, NP-

specific  $T_{s3}$  cells from  $(B6 \times C3H)F_1$  mice were used for the preparation of a series of  $F_1$ -derived  $T_{s3}$  hybridomas.

#### *Screening of Hybridoma Suppressor Cells*

$T_{s3}$  Suppressor cells were induced by priming  $(B6 \times C3H)F_1$  mice with 2 mg NP-O-Su s.c.  $T_{s3}$  cells were purified from regional lymph nodes by successive passage over RAMG- and NP-BSA-coated plates. The NP-BSA-adherent T cells were fused with the AKR-derived BW5147 thymoma line with polyethylene glycol; selection of hybridomas seeded at a concentration of  $10^4$  lymph node T cells per well was carried out with hypoxanthine-aminopterin-thymidine selective media. Hybridoma colonies were noted in  $\sim 50\%$  of the wells seeded. When the colonies were large enough for passage, an aliquot of cells was tested for the presence of I-J alloantigenic determinants by microcytotoxicity testing. 23% of the colonies tested demonstrated at least  $\pm$  reactions with at least one allele-specific anti-I-J alloantiserum. Supernatants from these colonies were screened for in vivo suppression of NP-specific CS responses. 0.5 ml of supernatant fluid was given i.v. on the day before, and the day of, antigen challenge to  $(B6 \times C3H)F_1$  mice. Four cell lines that manifested significant levels of suppression were saved for further analysis.

The four hybridoma cell lines that produced suppressor factors were examined for other cell surface markers by microcytotoxicity testing (data not shown). All functional  $(B6 \times C3H)F_1$  hybridoma cell lines were lysed with anti-I-J<sup>b</sup> and anti-I-J<sup>k</sup> alloantisera. However, as noted with other  $T_s$  hybridoma cell lines (27), the percentage of lysis was usually weak ( $<40\%$ ) and with continued in vitro culture the ability to lyse these cells was lost or became highly variable. Antiidiotypic reagents (anti-NP<sup>b</sup>) prepared against purified C57BL/6 anti-NP or anti-NIP serum antibodies were specifically lytic for the  $(B6 \times C3H)F_1$ - $T_{s3}$ -1032 and  $(B6 \times C3H)F_1$ - $T_{s3}$ -1114 hybridoma cells, but were not lytic for the  $(B6 \times C3H)F_1$ - $T_{s3}$ -1127 and  $(B6 \times C3H)F_1$ - $T_{s3}$ -1131 lines. In contrast, the antiidiotypic reagents (anti-NP<sup>j</sup>) prepared against purified C3H anti-NP antibodies were lytic for  $(B6 \times C3H)F_1$ - $T_{s3}$ -1131, but not for the other three cell lines. Again, the percentage of hybridoma cells lysed was generally low ( $<30\%$ ) and after prolonged in vitro culture the cells were no longer susceptible to lysis with these reagents. In contrast, all these  $(B6 \times C3H)F_1$ -derived hybridoma lines were readily lysed with either anti-Thy-1.1, anti-Thy-1.2, or anti-H-2D<sup>b</sup> antisera all of which yielded  $>80\%$  lysis even after prolonged in vitro culture (data not shown).

#### *Specificity of Suppressor Factors*

To test the biological activity of these four  $(B6 \times C3H)F_1$  hybridoma-derived suppressor factors, we screened for the ability of culture supernatants obtained from cells growing at a density of  $\sim 7 \times 10^5$  cells/ml to suppress in vivo NP or DNFB CS responses. Table II shows that i.v. injection of 0.5 ml of culture supernatant from the  $(B6 \times C3H)F_1$ - $T_{s3}$ -1032,  $(B6 \times C3H)F_1$ - $T_{s3}$ -1114,  $(B6 \times C3H)F_1$ - $T_{s3}$ -1127, and  $(B6 \times C3H)F_1$ - $T_{s3}$ -1131 cell lines specifically suppressed the NP-induced CS response in  $(B6 \times C3H)F_1$  mice. In this experiment the percent suppression ranged from 60 to 75%. In contrast, these culture supernatants could not suppress DNFB-induced CS responses. Furthermore, the data (Table III) demonstrate that these factors were only active in the effector phase

TABLE II  
Antigen Specificity of (B6 × C3H)<sub>F1</sub>-T<sub>s3</sub> Hybridoma Suppressor Factors<sup>‡</sup>

Recipient strain	Source of TsF	NP-O-Su footpad swelling ± SE <sup>§</sup>	DNFB ear swelling ± SE <sup>§</sup>
(B6 × C3H) <sub>F1</sub>	BW5147	30.0 ± 2.4	12.3 ± 1.5
	F1-T <sub>s3</sub> -1032	16.3 ± 0.9*	12.3 ± 0.9
	F1-T <sub>s3</sub> -1114	14.0 ± 2.4*	13.8 ± 1.8
	F1-T <sub>s3</sub> -1131	14.0 ± 0.6*	13.3 ± 0.9
	F1-T <sub>s3</sub> -1127	15.0 ± 0.6*	13.5 ± 1.6

<sup>‡</sup> Groups of four to five (B6 × C3H)<sub>F1</sub> mice were immunized with both NP-O-Su and DNFB. On the day before and the day of antigen challenge, mice were given 0.5 ml of control BW5147 or (B6 × C3H)<sub>F1</sub> hybridoma derived TsF<sub>s</sub>, i.v.

<sup>§</sup> The background responses of nonimmunized mice following antigen challenge were 7.8 ± 1.1 and 3.5 ± 0.3 × 10<sup>-3</sup> cm for NP-O-Su and DNFB, respectively. An asterisk indicates significant suppression, P < 0.01, compared with recipients which received control BW5147 factor.

TABLE III  
Comparison of the Ability of TsF to Suppress CS Responses in the Induction vs. Effector Phase<sup>‡</sup>

Strain of mice	Source of TsF	Time of TsF administration	
		Induction phase	Effector phase
(B6 × C3H) <sub>F1</sub>	BW5147	35.0 ± 0.3 <sup>§</sup>	43.2 ± 2.6
	CKB-T <sub>s1</sub> -17	12.5 ± 1.6*	ND
	F1-T <sub>s3</sub> -1032	35.0 ± 1.7	21.8 ± 3.1*
	F1-T <sub>s3</sub> -1114	35.0 ± 1.3	26.8 ± 2.5*
	F1-T <sub>s3</sub> -1127	36.0 ± 1.1	22.8 ± 2.0*
	F1-T <sub>s3</sub> -1131	34.0 ± 2.0	27.5 ± 0.9*

<sup>‡</sup> Groups of four to five (B6 × C3H)<sub>F1</sub> mice were immunized with NP-O-Su and were given TsF either at the time of antigen priming (induction phase) or antigen challenge (effector phase).

<sup>§</sup> Footpad swelling responses ± SE are indicated in units of 10<sup>-3</sup> cm. The level of background swelling in unprimed mice that had received the challenge was 10.3 ± 1.2. An asterisk indicates significant suppression, P < 0.01, compared to groups which received control BW5147-derived factor.

ND, not determined.

of the immune response. Thus, when 0.5 ml of factor was injected i.v. either on the day of and the day after antigen priming (induction phase) or the day before and the day of antigen challenge (effector phase), all the F<sub>1</sub>-derived factors only functioned in the effector phase. In confirmation of our previous data (25), the control CKB-T<sub>s1</sub>-17 inducer factor (TsF<sub>1</sub>) demonstrated suppressive activity when administered during the induction phase (Table III).

#### Genetic Restriction of (B6 × C3H)<sub>F1</sub>-T<sub>s3</sub> derived Factors

We had previously demonstrated that B6- or CKB-derived T<sub>s3</sub> hybridoma factors have a dual genetic restriction for both H-2 and Igh-linked genes.

Furthermore, the previous data (Table I) indicated that at least three and probably four distinct populations of Ts<sub>3</sub> cells restricted by either parental H-2 and Igh haplotype exist in H-2 and Igh heterozygous F<sub>1</sub> animals. However, in the latter experiments heterogeneous populations of T cells were used and the cells were tested in semi-allogeneic combinations in which allogeneic effects are difficult to exclude. Therefore, the production of monoclonal Ts<sub>3</sub> hybridomas from H-2 and Igh heterozygous F<sub>1</sub> mice permitted a more definitive analysis of the specificity of F<sub>1</sub>-derived Ts<sub>3</sub> cells and their factors. TsF<sub>3</sub> was administered i.v. during the effector phase of the NP-O-Su-induced CS response. Each F<sub>1</sub>-derived TsF<sub>3</sub> was tested in (B6 × C3H)F<sub>1</sub>, C57BL/6 (H-2<sup>b</sup>; Igh<sup>b</sup>), B10.BR (H-2<sup>k</sup>; Igh<sup>b</sup>), C3H/HeJ (H-2<sup>k</sup>; Igh<sup>j</sup>), and C3H.SW (H-2<sup>b</sup>; Igh<sup>j</sup>) recipients. As shown in Table IV each of the monoclonal (B6 × C3H)F<sub>1</sub>-derived TsF<sub>3</sub> factors are restricted to one parental H-2 and one parental Igh haplotype. Thus, (B6 × C3H)F<sub>1</sub>-Ts<sub>3</sub>-1032 and (B6 × C3H)F<sub>1</sub>-Ts<sub>3</sub>-1114 factors only suppress NP-induced CS responses of C57BL/6 (H-2<sup>b</sup>, Igh<sup>b</sup>) mice. These factors fail to suppress NP-induced CS responses in Igh disparate C3H.SW (H-2<sup>b</sup>, Igh<sup>j</sup>) recipients or H-2 congenic B10.BR (H-2<sup>k</sup>, Igh<sup>b</sup>) mice. Similarly, (B6 × C3H)F<sub>1</sub> Ts-1127 factor only suppressed NP-responses of C3H.SW (H-2<sup>b</sup>, Igh<sup>j</sup>) mice and (B6 × C3H)F<sub>1</sub>-Ts<sub>3</sub>-1131 factor only suppressed NP-CS responses of C3H (H-2<sup>k</sup>, Igh<sup>j</sup>) mice (Table IV).

To determine which subregions of the H-2 complex restricted the activity of these factors, one hybridoma (B6 × C3H)F<sub>1</sub>-Ts<sub>3</sub>-1032 was selected for further

TABLE IV  
Genetic Restrictions of (B6 × C3H)F<sub>1</sub> Hybridoma-derived TsF<sub>3</sub> Factors<sup>‡</sup>

TsF <sub>3</sub> source	Normalized Percent Suppression in Various Recipient Strains ± SE <sup>§</sup>				
	(B6 × C3H)F <sub>1</sub> (H-2 <sup>b</sup> /H-2 <sup>k</sup> ; Igh <sup>b</sup> /Igh <sup>j</sup> )	C57BL/6 (H-2 <sup>b</sup> ; Igh <sup>b</sup> )	B10.BR (H-2 <sup>k</sup> ; Igh <sup>b</sup> )	C3H (H-2 <sup>k</sup> ; Igh <sup>j</sup> )	C3H.SW (H-2 <sup>b</sup> ; Igh <sup>j</sup> )
BW5147	0 ± 4 (21)	0 ± 2 (21)	0 ± 4 (14)	0 ± 4 (17)	0 ± 4 (20)
(B6 × C3H)F <sub>1</sub> -Ts <sub>3</sub> -1032	52 ± 6 (8)*	67 ± 5 (12)*	22 ± 12 (11)	11 ± 6 (7)	-1 ± 5 (8)
(B6 × C3H)F <sub>1</sub> -Ts <sub>3</sub> -1114	48 ± 6 (15)*	43 ± 8 (16)*	9 ± 6 (13)	6 ± 5 (11)	15 ± 10 (12)
(B6 × C3H)F <sub>1</sub> -Ts <sub>3</sub> -1127	45 ± 3 (15)*	-14 ± 10 (8)	13 ± 7 (8)	10 ± 4 (13)	88 ± 5 (16)*
(B6 × C3H)F <sub>1</sub> -Ts <sub>3</sub> -1131	47 ± 3 (15)*	-5 ± 7 (12)	8 ± 5 (12)	68 ± 5 (16)*	6 ± 11 (16)

<sup>‡</sup> Groups of mice were immunized with NP-O-Su and were given TsF<sub>3</sub> on the day before and the day of antigen challenge.

<sup>§</sup> The data represent the pooled results from three separate experiments. The data were normalized and the percent suppression ± SE was calculated. The number of mice tested is indicated in parentheses. An asterisk indicates significant levels of suppression, *P* < 0.01.

TABLE V  
Intra H-2 Mapping of (B6 × C3H)F<sub>1</sub>-Ts<sub>3</sub>-1032 Derived Factor<sup>‡</sup>

Source of TsF	Normalized percent suppression ± SE <sup>§</sup>			
	C57BL/6 (H-2 <sup>b</sup> ; Igh <sup>b</sup> )	B.C.-8 (H-2 <sup>b</sup> ; Igh <sup>a</sup> )	B10.A(3R) (Ij <sup>b</sup> ; Igh <sup>b</sup> )	B10.A(5R) (Ij <sup>k</sup> ; Igh <sup>b</sup> )
BW5147	0 ± 6	0 ± 5	0 ± 7	0 ± 5
F1-Ts <sub>3</sub> -1032	73 ± 7*	-2 ± 7	70 ± 7*	3 ± 10

<sup>‡</sup> Groups of 4–8 mice were immunized with NP-O-Su and were given TsF on the day before and the day of antigen challenge.

<sup>§</sup> The data represent the normalized percent suppression of ± SE. An asterisk indicates significant suppression, *P* < 0.01.



analysis. TsF<sub>3</sub> derived from this hybridoma was tested in C57BL/6 (H-2<sup>b</sup>, Igh<sup>b</sup>), B.C-8 (H-2<sup>b</sup>, Igh<sup>a</sup>), B10.A (3R) (K<sup>b</sup>, IA<sup>b</sup>, IB<sup>b</sup>, IJ<sup>b</sup>, IE<sup>k</sup>, IC<sup>d</sup>, S<sup>d</sup>, D<sup>d</sup>; Igh<sup>b</sup>), and B10.A(5R) (K<sup>b</sup>, IA<sup>b</sup>, IB<sup>b</sup>, IJ<sup>k</sup>, IE<sup>k</sup>, IC<sup>d</sup>, S<sup>d</sup>, D<sup>d</sup>; Igh<sup>b</sup>) NP-primed mice. As shown in Table V, (B6 × C3H)F<sub>1</sub>-Ts<sub>3</sub>-1032 factor suppressed NP responses in C57BL/6 mice and B10.A(3R) mice, but failed to suppress NP responses in B10.A(5R) and Igh congenic B.C-8 recipients. Thus, the suppressive activity mediated by (B6 × C3H)F<sub>1</sub>-Ts<sub>3</sub>-1032-derived factor is restricted by I-J and Igh-linked genes.

*Immunochemical Characterization of (B6 × C3H)F<sub>1</sub>-Ts<sub>3</sub>-derived Factors*

The results of previous experiments demonstrated that TsF<sub>3</sub> factors derived from C57BL/6 (H-2<sup>b</sup>, Igh<sup>b</sup>) donors reacted with anti-I-J<sup>b</sup> and anti-NP<sup>b</sup> antisera (7). Furthermore, additional indirect evidence predicted that C3H-derived TsF<sub>3</sub> would react with anti-I-J<sup>k</sup> and anti-NP<sup>j</sup> antisera (7, 12). Thus, it is important to determine which I-J and Igh allelic products are expressed on the (B6 × C3H)F<sub>1</sub> derived TsF<sub>3</sub> and to determine whether these determinants correlate with the genetic restrictions of the factors. Therefore, three of the factors were passed over a series of immunoabsorbent columns. As shown in Table VI, the suppressive activity of (B6 × C3H)F<sub>1</sub>-Ts<sub>3</sub>-1032 factor which was restricted to C57BL/6 (Igh<sup>b</sup>) could be depleted by passage over anti-NP<sup>b</sup> but not anti-NP<sup>j</sup> columns. Furthermore, the suppressive activity could be specifically recovered following acid elution. In contrast, the suppressive activity of (B6 × C3H)F<sub>1</sub>-Ts<sub>3</sub>-1131 and (B6 × C3H)F<sub>1</sub>-Ts<sub>3</sub>-1127-derived factors which suppressed NP-responses in C3H mice (Igh<sup>j</sup>) or C3H.SW (Igh<sup>j</sup>) mice, respectively, were adsorbed by anti-NP<sup>j</sup> columns but not by anti-NP<sup>b</sup> immunoabsorbent columns.

In another series of experiments these factors were passed over several anti-I-J columns. The suppressive activity of the control C57BL/6-derived B6-Ts<sub>3</sub>-2 factor could be depleted by passage over a monoclonal anti-I-J<sup>b</sup> (WF9-40.5) column or columns made by coupling conventional anti-I-J<sup>b</sup> alloantiserum (anti-I-J<sup>b</sup>) and the activity could be recovered by acid elution (Table VII). In contrast, the suppressive activity of a control CKB-derived CKB-Ts<sub>3</sub>-9 factor was adsorbed by two different batches of monoclonal anti-I-J<sup>k</sup> (WF8.C2.4 and WF8.D2.4) or

TABLE VI  
*Fractionation of Hybridoma-derived Suppressor Factors on Antiidiotypic Columns<sup>‡</sup>*

Antiidiotypic column	Fraction	F <sub>1</sub> -Ts <sub>3</sub> -1032 <sup>‡</sup>	F <sub>1</sub> -Ts <sub>3</sub> -1127	F <sub>1</sub> -Ts <sub>3</sub> -1131
None	Unfractionated	54 ± 11*	64 ± 9*	55 ± 6*
Anti-NP <sup>b</sup>	Eluate	58 ± 6*	9 ± 8	-17 ± 11
	Filtrate	0 ± 3	60 ± 9*	63 ± 6*
Anti-NP <sup>j</sup>	Eluate	-4 ± 6	51 ± 7*	52 ± 8*
	Filtrate	35 ± 9*	4 ± 13	-8 ± 8

<sup>‡</sup> C57BL/6, C3H.SW or C3H mice were used as recipients of (B6 × C3H)F<sub>1</sub>-Ts<sub>3</sub>-1032, (B6 × C3H)F<sub>1</sub>-Ts<sub>3</sub>-1127 or (B6 × C3H)F<sub>1</sub>-Ts<sub>3</sub>-1131 factor, respectively. The mice were primed with NP-O-Su. On the day before and the day of antigen challenge, 0.5 ml of the designated column fractions were injected i.v.

<sup>§</sup> The data represent the pooled and normalized percent suppression from two or three separate experiments for each factor. An asterisk indicates significant suppression, *P* < 0.01.

TABLE VII  
*Fractionation of Hybridoma-derived Factors on Anti-I-J Immunoabsorbent Columns<sup>‡</sup>*

Anti-I-J column	Fraction	B6-Ts <sub>3</sub> -2	CKB-Ts <sub>3</sub> -9	F <sub>1</sub> -Ts <sub>3</sub> -1032	F <sub>1</sub> -Ts <sub>3</sub> -1127	F <sub>1</sub> -Ts <sub>3</sub> -1131
None	Unfractionated	44 ± 9*	41 ± 8*	81 ± 3*	74 ± 4*	42 ± 6*
WF8.C2.4	Eluate	5 ± 12	53 ± 10*	-2 ± 9	5 ± 9	56 ± 2*
	Filtrate	32 ± 6*	8 ± 6	43 ± 9*	76 ± 5*	2 ± 2
WF8.D2.3	Eluate	3 ± 7	48 ± 9*	2 ± 5	0 ± 5	35 ± 3*
	Filtrate	55 ± 8*	5 ± 10	65 ± 8*	73 ± 6*	-5 ± 11
WF9.40.5	Eluate	49 ± 2*	10 ± 3	58 ± 3*	85 ± 3*	1 ± 10
	Filtrate	-7 ± 8	46 ± 7*	0 ± 4	1 ± 4	45 ± 3*
Anti-I-J <sup>b</sup>	Eluate	33 ± 5*	5 ± 13	65 ± 4*	74 ± 5*	-1 ± 2
	Filtrate	-12 ± 3	49 ± 5*	1 ± 4	4 ± 6	62 ± 11*
Anti-I-J <sup>k</sup>	Eluate	-3 ± 3	50 ± 6*	4 ± 5	0 ± 5	46 ± 9*
	Filtrate	56 ± 4*	12 ± 9	60 ± 8*	80 ± 3*	3 ± 9

<sup>‡</sup> Groups of mice were primed with NP-O-Su. On the day before and the day of antigen challenge, 0.5 ml of the designated column fractions were injected i.v. C57BL/6 mice were recipients of B6-Ts<sub>3</sub>-2 and (B6 × C3H)F<sub>1</sub>-Ts<sub>3</sub>-1032 factor, B10.BR mice were recipients of CKB-Ts<sub>3</sub>-9 factor, C3H.SW recipients were given (B6 × C3H)F<sub>1</sub>-Ts<sub>3</sub>-1127 factor and C3H mice were given (B6 × C3H)F<sub>1</sub>-Ts<sub>3</sub>-1131 factor.

<sup>§</sup> The data represent the pooled and normalized percent suppression from one to three separate experiments for each factor. An asterisk indicates significant suppression,  $P < 0.01$ .

conventional anti-I-J<sup>k</sup> columns. Three (B6 × C3H)F<sub>1</sub>-Ts<sub>3</sub>-derived factors, (B6 × C3H)F<sub>1</sub>-Ts<sub>3</sub>-1032, (B6 × C3H)F<sub>1</sub>-Ts<sub>3</sub>-1127, and (B6 × C3H)F<sub>1</sub>-Ts<sub>3</sub>-1131, were passed over the same columns and the activity of the filtrate and eluate fractions were tested using C57BL/6, C3H.SW, and C3H mice, respectively. The suppressive activities of (B6 × C3H)F<sub>1</sub>-Ts<sub>3</sub>-1032 and (B6 × C3H)F<sub>1</sub>-Ts<sub>3</sub>-1127 factors were absorbed by monoclonal anti-I-J<sup>b</sup> (WF9-40.5) and conventional anti-I-J<sup>b</sup> columns. In contrast, the suppressive activity of (B6 × C3H)F<sub>1</sub>-Ts<sub>3</sub>-1131 factor was adsorbed by monoclonal and conventional anti-I-J<sup>k</sup> immunoabsorbents (Table VII). The I-J and Igh-related determinants on (B6 × C3H)F<sub>1</sub>-Ts<sub>3</sub>-1114 derived factor were not analyzed.

Thus, (B6 × C3H)F<sub>1</sub>-Ts<sub>3</sub>-1032 factor, which suppressed NP-responses in C57BL/6 (H-2<sup>b</sup>, Igh<sup>b</sup>) recipients, bears I-J<sup>b</sup> and NP<sup>b</sup>-related idiotypic determinants. Similarly, (B6 × C3H)F<sub>1</sub>-Ts<sub>3</sub>-1127 factor, which is specific for C3H.SW (H-2<sup>b</sup>, Igh<sup>j</sup>) recipients, bears I-J<sup>b</sup> and NP<sup>j</sup>-related idiotypic determinants. TsF<sub>3</sub> derived from (B6 × C3H)F<sub>1</sub>-Ts<sub>3</sub>-1131 hybridoma cells carries I-J<sup>k</sup> and NP<sup>j</sup>-related determinants and its activity is restricted to mice carrying the H-2<sup>k</sup> and Igh<sup>j</sup> haplotypes.

## Discussion

We had previously demonstrated that two distinct populations of Ts<sub>3</sub> cells, each restricted to one parental H-2 haplotype, existed in H-2 heterozygous F<sub>1</sub> mice (12). However, those previous studies never evaluated the Igh restrictions of the Ts<sub>3</sub> cells from Igh heterozygous donors. The present studies focus on this issue. Two independent approaches were used. First, heterogeneous populations of Ts<sub>3</sub> cells were induced in (B6 × C3H)F<sub>1</sub> donors and activated in vitro with monoclonal TsF<sub>2</sub>. The activated Ts<sub>3</sub> cells were adoptively transferred to Ts<sub>3</sub>-

depleted C57BL/6, C3H.SW, C3H, or CKB recipients. Strict genetic restrictions controlled the activation of the  $F_1$ -derived  $Ts_3$  populations. Thus, H-2 and Igh homology was always required between the  $TsF_2$  used for activation and the recipient strain (Table I). Thus, it appeared that four distinct  $Ts_3$  subpopulations, each with a distinct combination of restriction specificities, existed within H-2 and Igh heterozygous  $F_1$  animals. Although these conclusions describe the phenomena, they do not unravel the underlying mechanism responsible for the restrictions. One hypothesis to explain these restrictions is based on the previous demonstration that specialized populations of I-J-bearing antigen (or factor)-presenting cells are required for imposing I-J genetic restrictions on suppressor T cells (8, 9). Thus, to account for the restrictions between  $TsF_2$  and the recipients, we postulate that an I-J-bearing acceptor cell population is also involved in the presentation of  $TsF_2$ . Such cells could serve to juxtapose the  $TsF_2$  with the  $Ts_3$  cells, thereby permitting the interactions required for  $Ts_3$  activation. Furthermore, since suppressor cell interactions can occur in the absence of an external source of antigen (13, 25), the Igh restriction may reflect an antiidiotypic internal image (which substitutes for antigen). This hypothesis further suggests that such a system of internal images is in some fashion controlled by genes linked to the Igh complex. This speculative hypothesis, which attempts to account for the I-J and Igh restrictions, will require additional experimental support.

The second approach to analyzing  $Ts_3$  specificity involved the hybridization of  $(B6 \times C3H)F_1$ -derived  $Ts_3$  cells with the BW5147 thymoma. This approach led to the production of four monoclonal hybridoma cell lines. The hybridomas constitutively secreted soluble factors ( $TsF_3$ ) that mediated NP-specific effector phase suppressor activity (Tables II and III). The evidence that these hybridomas represented  $Ts_3$  cells included these facts: (a) the methods of induction and enrichment were based on those used to identify the  $Ts_3$  population, (b) the hybridomas had I-J and  $NP^b$  phenotypes characteristic of  $Ts_3$  cells, (c) the hybridoma cells produced NP-specific soluble suppressor factors that only functioned in the effector phase of the immune response in an H-2 (I-J), and Igh-restricted fashion, (d) the factors were active in cyclophosphamide treated recipients (data not shown), and (e) the factors specifically bound to columns containing allele-specific anti-I-J and antiidiotypic antibodies. All the above features are characteristic of  $Ts_3$  cells and their factors and permit one to distinguish  $Ts_3$  cells from the other suppressor cells and factors of the NP suppressor cell cascade.

The production of these  $(B6 \times C3H)F_1$ -derived  $Ts_3$  hybridomas permitted analysis of the genetic restrictions at the clonal level. In conformation of the adoptive transfer data (Table I), we noted that each hybridoma was restricted to one of the parental H-2 and Igh haplotypes. Of the four hybridomas characterized, we noted three distinct restriction specificities, including one clone,  $(B6 \times C3H)F_1$ - $Ts_3$ -1131, which was restricted by H-2<sup>k</sup>- and Igh<sup>j</sup>-linked genes (Table IV). The corresponding subpopulation in primed lymph node cells could not be identified using the adoptive transfer protocol, since C3H-derived  $TsF_2$  was not available. Factors derived from  $(B6 \times C3H)F_1$ - $Ts_3$ -1127 cells specifically suppressed NP responses in C3H.SW (H-2<sup>b</sup>; Igh<sup>j</sup>) recipients (Table IV). Thus, the

latter F<sub>1</sub> hybridoma clone demonstrated a "scrambled" restriction specificity, i.e., the H-2<sup>b</sup> restriction specificity was derived from the C57BL/6 parent and the Igh<sup>j</sup> restriction specificity was derived from the C3H parent. Additional data supporting the notion of "scrambled" restriction specificities was obtained from the adoptive transfer experiments in which in vitro-activated (B6 × C3H)F<sub>1</sub>-derived Ts<sub>3</sub> subpopulations specific for C3H.SW (H-2<sup>b</sup>; Igh<sup>j</sup>) and CKB (H-2<sup>k</sup>; Igh<sup>b</sup>) recipients were identified. The above results imply that the scrambled genetic restrictions may be a consequence of a receptor or an acceptor on the Ts<sub>3</sub> population that recognizes a combined Igh and MHC specificity present in the F<sub>1</sub> recipients, and/or that the Igh and H-2 receptors responsible for these scrambled genetic restrictions are separately encoded in the genome and demonstrate independent assortment in F<sub>1</sub> cells.

Another important purpose of these studies was to evaluate any correlations between the I-J and idiotype-related determinants present on the F<sub>1</sub>-derived Ts<sub>3</sub> hybridoma cells and their factors. The level of complement-mediated lysis of these and other hybridoma cells using specific anti-I-J alloantisera, was variable (27, 28). Although there have been claims that this variability was dependent on the cell cycle (29), little is known about such parameters. Our initial screening suggested that all four F<sub>1</sub>-derived hybridoma cell lines reacted with both anti-I-J<sup>b</sup> and anti-I-J<sup>k</sup> alloantisera. Previous studies have also indicated that both parental I-J alleles are expressed on H-2 heterozygous F<sub>1</sub>-derived T cells (12, 30). In contrast, the monoclonal suppressor factors derived from these F<sub>1</sub> hybridoma cells reacted with only one set of allele-specific anti-I-J reagents. Both conventional alloantisera and monoclonal anti-I-J reagents, specific for I-J<sup>b</sup> and I-J<sup>k</sup> allelic products, were used to examine the F<sub>1</sub>-derived factors (Table VII). Either one of the TsF<sub>3</sub> products secreted from each of the hybridomas was nonfunctional or the molecules derived from F<sub>1</sub> hybridomas only carry one set of I-J determinants even though both I-J allelic products may be expressed on the cell surface. Data in another system also suggest that H-2 heterozygous F<sub>1</sub> cells may produce TsF with only one parental I-J determinant (21), however, the phenotype of the Ts cells in those experiments was not determined.

The correlation between the phenotypic expression of Igh-controlled idiotype-related determinants of the F<sub>1</sub>-derived cells and factors was more consistent. Thus, the (B6 × C3H)F<sub>1</sub>-Ts<sub>3</sub>-1032 cells were lysed with anti-NP<sup>b</sup>, but not anti-NP<sup>j</sup> reagents, while the (B6 × C3H)F<sub>1</sub>-Ts<sub>3</sub>-1132 cells demonstrated the reciprocal pattern. Furthermore, the TsF<sub>3</sub> derived from these hybridomas specifically bound to immunoadsorbent columns containing the appropriate allele-specific antiidiotypic reagents. Cells from one hybridoma, (B6 × C3H)F<sub>1</sub>-Ts<sub>3</sub>-1127 were not lysed by either antiidiotypic reagent, but TsF<sub>3</sub> derived from these cells was specifically bound by an anti-NP<sup>j</sup> immunoadsorbent column. This finding suggested that the sensitivity of the column adsorptions was greater than that of the complement-mediated cytotoxicity tests. Nonetheless, the fact that the antiidiotypic reagents could be used to distinguish among the hybridoma cells and factors suggests that the idiotype-like determinants detected by these reagents are allelically excluded on F<sub>1</sub>-derived Ts<sub>3</sub> cells and factors. In contrast, there is codominant expression of I-J determinants on the F<sub>1</sub>-derived hybridoma cells, although there is functional allelic exclusion of I-J determinants on F<sub>1</sub>-derived

TsF<sub>3</sub>. It is interesting that F<sub>1</sub>-derived TsF<sub>3</sub> displays many of the same features of allelic exclusion as exhibited by immunoglobulins. Thus, in F<sub>1</sub>-derived B cells only one heavy chain and one light chain gene product is expressed (31). There have, however, been several examples of aborted heavy or light chain rearrangements that affect the other parental chromosome (32, 33). Although the latter gene products are generally not secreted, in selected instances, they are produced and can be detected in nonsecreted form (34).

A complete correlation was found between the determinants on F<sub>1</sub>-derived TsF<sub>3</sub> and the restriction specificity of these factors. Thus, among the three F<sub>1</sub> hybridoma-derived factors examined, those that were restricted to H-2<sup>b</sup>, reacted with anti-I-J<sup>b</sup> immunoadsorbent columns, whereas those restricted to H-2<sup>k</sup> were bound by anti-I-J<sup>k</sup> columns. Furthermore, when the activity of F<sub>1</sub>-derived TsF<sub>3</sub> was restricted to strains bearing Igh<sup>b</sup>-linked genes, the factors were bound by anti-NP<sup>b</sup> columns but not immunoadsorbent columns specific for anti-NP antibodies derived from mice carrying the Igh<sup>j</sup> haplotype. The latter antiidiotypic reagents were capable of specifically binding (B6 × C3H)F<sub>1</sub>-derived TsF<sub>3</sub>, the activity of which was restricted to strains bearing the Igh<sup>j</sup> haplotype. These findings appear to conflict with the observations of Yamauchi et al. (35), who reported that the Igh restriction specificity of spleen cell-derived TsF was controlled by the I-J-bearing chain. Although the factor described Yamauchi et al. is also a two-chain heterodimer, it was derived from Lyt-1+ inducer Ts. In contrast, the products described in the present report are derived from Lyt-2+ effector Ts; consequently direct comparisons of the present data with those of Yamauchi and colleagues may not be valid.

Some recent reports have indicated that the I-J region may not code for a gene product (36). These findings raise many questions as to the nature of the I-J products detected on T cells by this and many other laboratories (1-4, 16-18). In fact, what has been shown in all these reports is that antibodies produced in 3R-5R combinations can bind to suppressor cells and factors. We have recently examined this issue and concluded that the I-J determinants found on antigen-presenting cells (perhaps a modified I-E<sub>B</sub> gene product) may represent the restricting elements (8, 9). We postulated that the determinants detected on suppressor T cells and factors are anti-self I-J receptors that are recognized by antiidiotypic antibodies contaminating the conventional anti-I-J alloantisera (9). The monoclonal reagents used in this and other reports may also represent anti-receptor antibodies. In the current experiments, the restriction of TsF<sub>3</sub> to the I-J subregion matching the "I-J phenotype" of the factor may be attributed to recognition of I-J products present in the recipient by clonally restricted anti-self I-J receptors on TsF<sub>3</sub>. Since the NP-specific TsF<sub>3</sub> molecule consists of a disulfide-linked heterodimer, containing an antigen-binding chain and a second chain that reacts with anti-I-J antisera (11, 17), it is tempting to create a model of TsF<sub>3</sub> in which each chain controls a distinct restriction specificity, i.e. a two-receptor molecule.

Finally, it is important to evaluate the specificity of suppression in F<sub>1</sub> vs. parental recipients. In the various experiments performed using either the Ts<sub>3</sub> cell transfer protocol or the analysis of F<sub>1</sub>-derived TsF<sub>3</sub>, we noted that the magnitude of suppression was generally comparable in either parental or F<sub>1</sub>

recipients. If TsF<sub>3</sub> is specific for the receptors on CS effector cells we would expect a lower degree of suppression on the CS responses in H-2 heterozygous F<sub>1</sub> animals. Therefore, we must either entertain the possibility that the targets of Ts<sub>3</sub> cells or TsF<sub>3</sub> are not the CS effector population (2, 37, 38) and/or that the final suppressor mechanism may demonstrate bystander suppression (39, 40).

### Summary

In the 4-hydroxy-3-nitrophenyl acetyl (NP) contact sensitivity system, the activity of third-order suppressor cells and their factors is restricted by H-2(I-J) and Igh linked genes. The present report analyzes the specificity of NP-specific Ts<sub>3</sub> cells and factors derived from H-2 and Igh heterozygous (B6 × C3H)F<sub>1</sub> mice. Two approaches were used. First, heterogeneous populations of F<sub>1</sub> Ts<sub>3</sub> cells were activated in vitro and then assayed in Ts<sub>3</sub>-depleted recipients which carried different combinations of H-2 and Igh alleles. The second approach was to hybridize the Ts<sub>3</sub> cells and analyze the specificity of the F<sub>1</sub>-derived TsF<sub>3</sub>. The combined data demonstrated four functionally distinct populations of Ts<sub>3</sub> cells. The activity of each population was restricted by a particular combination of H-2 and Igh haplotypes. Thus, Ts<sub>3</sub> cells derived from F<sub>1</sub> donors can demonstrate an apparent scrambling of H-2 and Igh restriction specificities.

There was functional allelic exclusion of the H-2(I-J) and Igh determinants expressed on (B6 × C3H)F<sub>1</sub> hybridoma-derived TsF<sub>3</sub>. Thus, TsF<sub>3</sub> from each cloned hybridoma line expressed only one set of I-J and Igh determinants. Furthermore, there was a complete correlation between the I-J and Igh linked determinants expressed on TsF<sub>3</sub> and the restriction specificity.

In view of the recent findings on the molecular biology of the I-J region, an alternative interpretation of the role of I-J determinants on suppressor cells and factors is offered.

The authors express their appreciation to Mrs. N. Axelrod and M. J. Tawa for expert secretarial assistance and to Dr. D. H. Sherr for helpful discussions.

*Received for publication 18 April 1983.*

### References

1. Germain, R. N., and B. Benacerraf. 1981. A single major pathway of T-lymphocyte interactions in antigen-specific immune suppression. *Scand. J. Immunol.* 13:1.
2. Flood, P., K. Yamauchi, and R. K. Gershon. 1982. Analysis of the interactions between two molecules that are required for the expression of Ly-2 suppressor cell activity. Three different types of focusing events may be needed to deliver the suppressive signal. *J. Exp. Med.* 156:361.
3. Kapp, J. A., and B. A. Araneo. 1982. Antigen-specific suppressor T cell interactions. I. Induction of an MHC-restricted suppressor factor specific for L-glutamic acid<sup>50</sup>-L-tyrosine<sup>50</sup>. *J. Immunol.* 128:2447.
4. Claman, H. N., S. D. Miller, P. J. Conlon, and J. W. Moorhead. 1980. Control of experimental contact sensitivity. *Adv. Immunol.* 30:121.
5. Weinberger, J. Z., R. N. Germain, B. Benacerraf, and M. E. Dorf. 1980. Hapten-specific T-cell responses to 4-hydroxy-3-nitrophenyl acetyl. V. Role of idiotypes in the suppressor pathway. *J. Exp. Med.* 152:161.

6. Sunday, M. E., B. Benacerraf, and M. E. Dorf. 1981. Hapten specific T cell responses to 4-hydroxy-3-nitrophenyl acetyl. VIII. Suppressor cell pathways in cutaneous sensitivity responses. *J. Exp. Med.* 153:811.
7. Okuda, K., M. Minami, S. Furusawa, and M. E. Dorf. 1981. Analysis of T cell hybridomas. II. Comparisons among three distinct types of monoclonal suppressor factors. *J. Exp. Med.* 154:1838.
8. Minami, M., N. Honji, and M. E. Dorf. 1982. The mechanism responsible for the induction of I-J restrictions on Ts<sub>3</sub> suppressor cells. *J. Exp. Med.* 156:1502.
9. Aoki, I., M. Minami, and M. E. Dorf. 1983. A mechanism responsible for the induction of H-2 restricted second-order suppressor T cells. *J. Exp. Med.* 157:1726.
10. Sherr, D. H., and M. E. Dorf. 1981. Hapten-specific T cell responses to 4-hydroxy-3-nitrophenyl acetyl. IX. Characterization of idiotype-specific effector phase suppressor cells on plaque-forming cell responses in vitro. *J. Exp. Med.* 153:1445.
11. Sherr, D. H., M. Minami, K. Okuda, and M. E. Dorf. 1983. Analysis of T cell hybridomas. III. Distinctions between two types of hapten-specific suppressor factors which affect plaque-forming cell responses. *J. Exp. Med.* 157:515.
12. Minami, M., S. Furusawa, and M. E. Dorf. 1982. I-J restrictions on the activation and interaction of parental and F<sub>1</sub> derived Ts<sub>3</sub> suppressor cells. *J. Exp. Med.* 156:456.
13. Minami, M., K. Okuda, S. Furusawa, and M. E. Dorf. 1983. Analysis of T cell hybridomas. IV. Characterization of inducible suppressor cell hybridomas. *J. Exp. Med.* 157:1379.
14. Sherr, D. H., and M. E. Dorf. 1982. Hapten specific T cell responses to 4-hydroxy-3-nitrophenyl acetyl. XIII. Characterization of a third order T cell (Ts<sub>3</sub>) involved in suppression of in vitro PFC responses. *J. Immunol.* 128:1261.
15. Taniguchi, M., I. Takei, and T. Tada. 1980. Functional and molecular organisation of an antigen-specific suppressor factor from a T cell hybridoma. *Nature (Lond.)* 283:227.
16. Taniguchi, M., T. Saito, I. Takei, and T. Tokuhisa. 1981. Presence of interchain disulfide bonds between two gene products that compose the secreted form of an antigen-specific suppressor factor. *J. Exp. Med.* 153:1672.
17. Furusawa, S., M. Minami, D. H. Sherr, and M. E. Dorf. 1983. Analysis of the suppressor T cell cascade with products derived from T cell hybridomas. In *Cell Fusion*. R. F. Beers, Jr. and E. G. Basset, editors. Raven Press, New York. pp. 299-313.
18. Lei, H., S. T. Ju, M. E. Dorf, and C. Waltenbaugh. 1983. Regulation of immune responses by I-J gene products. III. GT-specific suppressor factor is composed of separate I-J and idiotype bearing chains. *J. Immunol.* 130:1274.
19. Okuda, K., M. Minami, S. T. Ju, and M. E. Dorf. 1981. Functional association of idiotypic and I-J determinants on the antigen receptor of suppressor T cells. *Proc. Natl. Acad. Sci. USA.* 78:4557.
20. Waltenbaugh, C. 1981. Regulation of immune responses by I-J gene products. I. Production and characterization of anti-I-J monoclonal antibodies. *J. Exp. Med.* 154:1570.
21. Lei, H. Y., M. E. Dorf, and C. Waltenbaugh. 1982. Regulation of immune responses of I-J gene products. II. Presence of both I-J<sup>b</sup> and I-J<sup>k</sup> suppressor factors in (nonsuppressor × nonsuppressor)F<sub>1</sub> mice. *J. Exp. Med.* 155:955.
22. Ju, S., B. Benacerraf, and M. E. Dorf. 1978. Idiotypic analysis of antibodies to poly(Glu<sup>60</sup>Ala<sup>30</sup>Tyr<sup>10</sup>): interstrain and interspecies idiotypic cross-reactions. *Proc. Natl. Acad. Sci. USA.* 75:6192.
23. Ju, S., and M. E. Dorf. 1981. Cross-induction of predominant NP<sup>b</sup> idiotypic antibodies with derivatives of (4-hydroxy-3-nitrophenyl) acetyl. *J. Immunol.* 127:2224.

24. Minami, M., K. Okuda, S. Furusawa, B. Benacerraf, and M. E. Dorf. 1981. Analysis of T cell hybridomas. I. Characterization of H-2 and Igh restricted monoclonal suppressor factors. *J. Exp. Med.* 154:1390.
25. Okuda, K., M. Minami, D. H. Sherr, and M. E. Dorf. 1981. Hapten-specific T cell responses to 4-hydroxy-3-nitrophenyl acetyl. XI. Pseudogenetic restrictions of hybridoma suppressor factors. *J. Exp. Med.* 154:468.
26. Sunday, M. E., J. Z. Weinberger, B. Benacerraf, and M. E. Dorf. 1980. Hapten-specific T cell responses to 4-hydroxy-3-nitrophenyl acetyl. IV. Specificity of cutaneous sensitivity responses. *J. Immunol.* 125:1601.
27. Dorf, M. E., K. Okuda, and M. Minami. 1982. Dissection of a suppressor cell cascade. *Curr. Top. Microbiol. Immunol.* 100:61.
28. Trial, J., J. A. Kapp, C. W. Pierce, D. C. Shreffler, C. M. Sorensen, and C. Waltenbaugh. 1983. Expression of cell surface antigens by suppressor T cell hybridomas. I. Comparison of phenotype and function. *J. Immunol.* 130:565.
29. Kanno, M., I. Takei, N. Suzuki, H. Tomioka, and M. Taniguchi. 1980. Periodic expression of antigen-binding and I-J molecules on the Ts hybridoma. *Proc. Jpn. Soc. Immunol.* 10:41.
30. Okuda, K., C. S. David, and D. C. Shreffler. 1977. The role of gene products of the I-J subregion in mixed lymphocyte reactions. *J. Exp. Med.* 146:1561.
31. Pernis, B., G. Chiappino, A. S. Kelus, and P. G. H. Gell. 1965. Cellular localization of immunoglobulins with different allotypic specificities in rabbit lymphoid tissues. *J. Exp. Med.* 122:853.
32. Perry, R. P., D. E. Kelley, C. Coleclough, J. G. Seidman, P. Leder, S. Tonegawa, G. Mathysens, and M. Weigert. 1980. Transcription of mouse kappa chain genes: implications for allelic exclusion. *Proc. Natl. Acad. Sci. USA.* 77:1937.
33. Hieter, P. A., S. J. Korsmeyer, G. F. Hollis, E. E. Max, J. V. Maizel, T. A. Waldmann, and P. Leder. 1981. Immunoglobulin light chain genes of mouse and man. In *Immunoglobulin Idiotypes*. C. Janeway, E. E. Sercarz, and H. Wigzell editors. Academic Press, New York. p. 33.
34. Schwartz, R. C., G. E. Sonenshein, A. Bothwell, and M. L. Gefter. 1981. Multiple expression of Ig lambda-chain encoding RNA species in murine plasmacytoma cells. *J. Immunol.* 126:2104.
35. Yamauchi, K., N. Chao, D. B. Murphy, and R. K. Gershon. 1982. Molecular composition of an antigen-specific, Ly-1 suppressor inducer factor. One molecule binds antigen and is I-J<sup>-</sup>; another is I-J<sup>+</sup>, does not bind antigen, and imparts an Igh-variable region linked restriction. *J. Exp. Med.* 155:655.
36. Steinmetz, M., K. Minard, S. Horvath, J. McNicholas, J. Srelinger, C. Wake, E. Long, B. Mach, and L. Hood. 1982. A molecular map of the immune response region from the major histocompatibility complex of the mouse. *Nature (Lond.)* 300:35.
37. Ptak, W., M. Zembala, and R. K. Gershon. 1978. Intermediary role of macrophages in the passage of suppressor signals between T-cell subsets. *J. Exp. Med.* 148:424.
38. Asherson, G. L., and M. Zembala. 1982. The role of the T acceptor cell in suppressor systems: antigen-specific T suppressor factor acts via a T acceptor cell: this releases a non-specific inhibitor of the transfer of contact sensitivity when exposed to antigen in the context of I-J. *Ann. N. Y. Acad. Sci.* 392:71.
39. Taniguchi, M., and T. Tokuhisa. 1980. Cellular consequences in the suppression of antibody response by the antigen-specific T cell factor. *J. Exp. Med.* 151:517.
40. Fresno, M., L. Mcvay-Boudreau, and H. Cantor. 1982. Antigen-specific T lymphocyte clones. III. Papain splits purified T suppressor molecules into two functional domains. *J. Exp. Med.* 155:981.